UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty ...
ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...
US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug ...
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...
Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from ...
US clinical-stage US autoimmune drug developerKyverna Therapeutics (Nasdaq: KYTX) and ElevateBio, a contract development and manufacturing organization (CDMO), today announced a manufacturing ...
Three weeks after the UK launch of Danish pharma major Novo Nordisk’s (NOV: N) daily Wegovy Pill (semaglutide), weight health provider CheqUp says early demand indicates strong consumer interest in a ...
French pharma Ipsen (Euronext: IPN) has reported that its Phase III BOLD trial of Bylvay (odevixibat) in biliary atresia failed to meet its primary endpoint, dealing a setback to efforts to develop ...
US biotech Outlook Therapeutics revealed that the US Food and Drug Administration (FDA) has approved Lytenava ...
UK-based Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA ...
A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results